Source: CureToday articles
Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.
Recent Content
- True Grit: The Spirit of an Extraordinary Healer
- Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma
- Uniting Pediatric and Adult Oncologists to Advance AYA Lymphoma Care
- Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma
- Oral GLP-1 Agonist Orforglipron Shows Promise for Type 2 Diabetes and Weight Management
- Making Something Positive out of Breast Cancer
- Promising Early Results for Linvoseltamab Combinations in Relapsed/Refractory Multiple Myeloma
- FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
- FDA Approves Mepolizumab for Treatment of Patients With COPD and an Eosinophilic Phenotype
- Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL